The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Nedogoda S.V.

Volgograd State Medical University

Chumachek E.V.

Volgograd State Medical University

Ledyaeva A.A.

Volgograd State Medical University

Tsoma V.V.

Volgograd State Medical University

Vlasov D.S.

Volgograd State Medical University

Bychkova O.I.

Medical Department of the Federal Security Service of Russia in the Volgograd Region

Non-fixed combination perindopril+moxonidine for angioprotection in hypertensive patients with metabolic syndrome

Authors:

Nedogoda S.V., Chumachek E.V., Ledyaeva A.A., Tsoma V.V., Vlasov D.S., Bychkova O.I.

More about the authors

Journal: Russian Journal of Cardiology and Cardiovascular Surgery. 2021;14(6): 499‑504

DOI: 10.17116/kardio202114061499

Read: 2044 times

Download PDF (RU)
Contact the author
Table of contents

NON-FIXED COMBINATION PERINDOPRIL+MOXONIDINE FOR ANGIOPROTECTION IN HYPERTENSIVE PATIENTS WITH METABOLIC SYNDROME
NON-FIXED COMBINATION PERINDOPRIL+MOXONIDINE FOR ANGIOPROTECTION IN HYPERTENSIVE PATIENTS WITH METABOLIC SYNDROME

To cite this article:

Nedogoda SV, Chumachek EV, Ledyaeva AA, Tsoma VV, Vlasov DS, Bychkova OI. Non-fixed combination perindopril+moxonidine for angioprotection in hypertensive patients with metabolic syndrome. Russian Journal of Cardiology and Cardiovascular Surgery. 2021;14(6):499‑504. (In Russ.)
https://doi.org/10.17116/kardio202114061499

 
ЭндоКард
Подписка 2026 Кардиология и сердечно-сосудистая хирургия (Russian Journal of Cardiology and Cardiovascular Surgery)
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
The possibilities of Mexi­dol in the complex therapy of arte­rial hype­rtension. Russian Journal of Cardiology and Cardiovascular Surgery. 2024;(5):572-580
Inte­rnational multicenter randomized double-blind placebo-controlled study asse­ssing the effi­cacy and safety of sequential therapy with Mexi­dol and Mexi­dol FORTE 250 in patients with chro­nic brain ischemia (MEMO): suba­nalysis in patients with arte­rial hype­rtension. Russian Journal of Preventive Medi­cine. 2024;(10):72-83
Reso­lution of the expert council «Possibilities of neuroprotective therapy in patients with arte­rial hype­rtension and cognitive diso­rders». Russian Journal of Preventive Medi­cine. 2024;(11):85-93
The significance of exogenous nitrate and nitrite of plant origin for vascular health. Russian Journal of Preventive Medi­cine. 2024;(11):141-146
Predictors of Enga­gement and Active participation of Patients with Unco­ntrolled Hype­rtension in the Tele­health Surveillance Program. Russian Journal of Preventive Medi­cine. 2024;(12):37-43
The role of quantitative body composition analysis in popu­lation in the asse­ssment and moni­toring of cardiovascular risk meta­bolic factors. Russian Journal of Preventive Medi­cine. 2024;(12):128-134
Cuffless methods of blood pressure measurements. Review of modern technologies. Russian Journal of Preventive Medi­cine. 2024;(12):156-162
Deve­lopment of a method for moxo­nidine quantification in blood and urine by high-performance liquid chro­matography with tandem mass-selective dete­ction. Fore­nsic Medi­cal Expe­rtise. 2024;(6):42-47
Modern aspe­cts of chro­nic cere­bral ischemia pathogenetic therapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):106-113
Influence of enzy­matic acti­vity of microbiota on hemo­dynamics, arte­rial stiffness and emotional state of patients with mild-to-moderate risk of cardiovascular complications. Russian Cardiology Bulletin. 2024;(4-2):128-136
Abstract:

OBJECTIVE

To evaluate the efficacy of perindopril + moxonidine non-fixed combination in improving the arterial elasticity in hypertensive patients with metabolic syndrome and previous combined antihypertensive therapy.

MATERIAL AND METHODS

An open observational 24-week study included 72 patients with previous dual antihypertensive therapy and blood pressure (BP) >130/80 mm Hg. All patients underwent ambulatory BP monitoring, applanation tonometry (assessment of augmentation index and central blood pressure), pulse wave velocity (PWV) measurement, laboratory tests (lipid profile, fasting glucose, HOMA index, leptin, hsCRP).

RESULTS

Perindopril + moxonidine 0.4 mg or 0.6 mg non-fixed combination provided systolic BP reduction by 24.8% and 20.9%, diastolic BP by 19.4% and 17.4% (p<0.05), PWV by 25.1% and 22.8%, augmentation index by 17.1% and 15.2%, vascular age by 8.3 years and 7.6 years, respectively (p<0.05). Leptin level decreased by 18% and 6.7%, hsCRP by 34.1% and 31.2%, HOMA index by 7.7% and 4.8%, respectively (p<0.05).

CONCLUSION

Perindopril + moxonidine non-fixed combination has advantages in BP control, arterial elasticity improving, suppression of insulin-resistance and inflammation.

Keywords:

arterial hypertension
pulse wave velocity
central blood pressure
augmentation index
combined antihypertensive therapy
perindopril
moxonidine

Authors:

Nedogoda S.V.

Volgograd State Medical University

Chumachek E.V.

Volgograd State Medical University

Ledyaeva A.A.

Volgograd State Medical University

Tsoma V.V.

Volgograd State Medical University

Vlasov D.S.

Volgograd State Medical University

Bychkova O.I.

Medical Department of the Federal Security Service of Russia in the Volgograd Region

Received:

15.10.2021

Accepted:

11.11.2021

Close metadata

References:

  1. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). European Heart Journal. 2018;39(33):3021-3104. https://doi.org/10.1093/eurheartj/ehy339
  2. Shlyakhto EV, Kobalava ZhD, Konradi AO, Nedogoda SV, et al. Guidelines for the management of arterial hypertension. (In Russ.) https://scardio.ru/content/Guidelines/Clinic_rek_AG_2020.pdf
  3. Laurent S, Boutouyrie P, Asmar R, Gautier I, Laloux B, Guize L. Aortic stiffness is an independent predictor of all cause and cardiovascular mortality in hypertensive patients. Hypertension. 2001;37:1236-1241. https://doi.org/10.1161/01.HYP.37.5.1236
  4. Boutouyrie P, Tropeano AI, Asmar R, Gautier I, Benetos A, Lacolley P. Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: a longitudinal study. Hypertension. 2002;39:10-15.  https://doi.org/10.1161/hy0102.099031
  5. Mattace-Raso FU, Cammen TJ, Hofman A, Popele NM, Bos ML, Schalekamp MA. Arterial stiffness and risk of coronary heart disease and stroke: the Rotterdam study. Circulation. 2006;113:657-663.  https://doi.org/10.1161/circulationaha.105.555235
  6. Laurent S, Katsahian S, Fassot C, Tropeano AI, Laloux B, Boutouyrie P. Aortic stiffness is an independent predictor of fatal stroke in essential hypertension. Stroke. 2003;34:1203-1206. https://doi.org/10.1161/01.str.0000065428.03209.64
  7. Laurent S, Cockcroft J, Bortel LV, Boutouyrie P, Giannattasio C, Hayoz D, Pannier B, Vlachopoulos C. Expert consensus document on arterial stiffness: methodological issues and clinical applications. European Heart Journal. 2006;21:2588-2605. https://doi.org/10.1093/eurheartj/ehl254
  8. Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, Hughes AD, Thurston H, O’Rourke M. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: Principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation. 2006;113:1213-1225. https://doi.org/10.1161/CIRCULATIONAHA.105.595496
  9. Cuende JI, Cuende N, Calaveras-Lagartos J. How to calculate vascular age with the SCORE project scales: a new method of cardiovascular risk evaluation. Eur Heart J. 2010;31(19):2351-2358. https://doi.org/10.1093/eurheartj/ehq205
  10. Gardner JP, Li S, Srinivasan SR, et al. Rise in insulin resistance is associated with escalated telomere attrition. Circulation. 2005;111:2171-2177. https://doi.org/10.1161/01.cir.0000163550.70487.0b
  11. Houben JMJ. Telomere length assessment: biomarker of chronic oxidative stress? Free Radic Biol Med. 2008;44(3):235-246.  https://doi.org/10.1016/j.freeradbiomed.2007.10.001
  12. Sengstock DM, Vaitkevicius PV, Supiano MA. Arterial stiffness is related to insulin resistance in nondiabetic hypertensive older adults. J Clinical Endocrinol & Metabol. 2005;90(5):2823-2827. https://doi.org/10.1210/jc.2004-1686
  13. Ionescu DD. PREFER Investigators. Antihypertensive efficacy of perindopril 5-10 mg/day in primary health care: An open-label, prospective, observational study. Clin Drug Investig. 2009;29(12):767-776.  https://doi.org/10.2165/11319700-000000000-00000
  14. Koz C, Baysan O, Yokusoglu M, et al. The effects of perindopril on aortic elasticity and inflammatory markers in hypertensive patients. Med Sci Monit. 2009;15(7):PI 41-45. 
  15. Prichard BN, Jäger BA, Luszick JH, et al. Placebo-controlled comparison of the efficacy and tolerability of once-daily moxonidine and enalapril in mild to moderate essential hypertension. Blood Press. 2002;11(3):166-172.  https://doi.org/10.1080/080370502760050403
  16. Frei M, Küster L, Gardosch von Krosigk PP, et al. Moxonidine and hydrochlorothiazide in combination: A synergistic antihypertensive effect. J Cardiovasc Pharmacol. 1994;24(Suppl 1):25-28. 
  17. Waters J, Ashford J, Jager BA, et al. Use of moxonidine as unitial therapy and in combination in the treatment of essential hypertension: Results of the TOPIC study. J Clin Basic Cardiol. 1999;2:219-224. 
  18. Lumb PJ, McMahon Z, Chik G, Wierzbicki AS. Effect of moxonidine on lipid subfractions in patients with hypertension. Int J Clin Pract. 2004;58:465-468. 
  19. Velliquette RA, Kossover R, Previs SF, Ernsberger P. Lipid-lowering actions of imidazoline antihypertensive agents in metabolic syndrome X. Naunyn Schmiedebergs Arch Pharmacol. 2006;372:300-312.  https://doi.org/10.1007/s00210-005-0024-3
  20. Edwards LP, Brown-Bryan TA, McLean L. Pharmacological properties of the central antihypertensive agent moxonidine. Cardiovascular Therapeutics. 2011;00:1-10.  https://doi.org/10.1111/j.1755-5922.2011.00268.x
  21. Nascimento AR, Lessa MA, Sabino B, et al. Microvascular effects of centrally acting antihypertensive drugs in spontaneously hypertensive rats. Journal of Cardiovascular Pharmacology. 2010;55(3):240-247.  https://doi.org/10.1097/FJC.0b013e3181ce9810
  22. Skibitskiy VV, Gutova SR, Fendrikova AV, et al. Antihypertensive and Vasoprotective Effects of Combined Pharmacotherapy in Patients with Arterial Hypertension and Prediabetes. Kardiologiya. 2020;60(4):10-17. (In Russ.). https://doi.org/10.18087/cardio.2020.4.n1112
  23. Bousquet P, Hudson A, García-Sevilla JA, Li J-X. Imidazoline Receptor system: the past, the present, and the future. Pharmacological Reviews. 2020;72(1):50-79.  https://doi.org/10.1124/pr.118.016311
  24. Topal E, Cikim AS, Cikim K, et al. The Effect of moxonidine on endothelial dysfunction in metabolic syndrome. American Journal of Cardiovascular Drugs. 2006;6(5):343-348.  https://doi.org/10.2165/00129784-200606050-00007
  25. Sarac B, Korkmaz O, Altun A. Investigation of the vasorelaxant effects of moxonidine and its relaxation mechanism on the human radial artery when used as a coronary bypass graft Interact. Cardiovasc Thorac Surg. 2015;21(3):342-345.  https://doi.org/10.1093/icvts/ivv136.
  26. Poyhonen-Alho MK, Manhem K, Katzman P, et al. Central sympatholytic therapy has anti-inflammatory properties in hypertensive postmenopausal women. J Hypertens. 2008;26:2445-2449. https://doi.org/10.1097/hjh.0b013e328311cf37
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.